Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 07, 2024

BUY
$32.76 - $39.56 $1.08 Million - $1.31 Million
33,100 Added 273.55%
45,200 $1.58 Million
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $175,450 - $459,800
12,100 New
12,100 $459,000
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $213,072 - $455,032
18,400 New
18,400 $330,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.